ReviewTransfusion2010
Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?
Review in Transfusion, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04468009 (Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.The Journal of infectious diseases · 2015Pooled it
- The effect of COVID-19 on blood donation habits.Transfusion · 2021Trial
- Polyclonal and Monoclonal Antibodies for the Treatment and Prevention of Influenza.The Journal of infectious diseases · 2025Review
- A Roadmap for the Application of Convalescent Plasma and Hyperimmune Globulins in Emerging Viral Outbreaks.TheScientificWorldJournal · 2025Review
- Use of Immunoglobulin Y Antibodies: Biosensor-based Diagnostic Systems and Prophylactic and Therapeutic Drug Delivery Systems for Viral Respiratory Diseases.Current topics in medicinal chemistry · 2024Review
- Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved.Heliyon · 2023Article
- Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.Viruses · 2023Article
- 'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.Infectious disorders drug targets · 2022Article
- Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Article
- The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.Life (Basel, Switzerland) · 2021Review
- Article
- Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities.Vox sanguinis · 2021Article
- Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry.Scientific reports · 2020Article
- Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020Article
- Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Article
- Emergency Nursing Care of Patients With Novel Coronavirus Disease 2019.Journal of emergency nursing · 2020Review
- Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.Transfusion · 2020Article
- Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.Virus research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral- and vaccine-based response to an influenza pandemic. One such countermeasure-the transfusion of pandemic influenza-specific antibodies from surviving patients to the clinically ill-is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP-Flu]) are discussed. FCP-Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP-Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.